1 Department of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d’Ivoire.
2 Hematology Unit, Central Laboratory, Yopougon University Hospital, Abidjan, Côte d’Ivoire.
3 Department of Hematology, Nîmes University Hospital, University of Montpellier, France.
4 Department of Pediatrics, Yopougon University Hospital, Abidjan, Côte d’Ivoire.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Type 3 von Willebrand disease (VWD) is the most severe form of VWD,
characterized by a near-total absence of von Willebrand factor (vWF),
leading to a massive deficiency in plasmatic factor VIII (FVIII). VWD
may be confused with hemophilia A, sometimes leading to misdiagnosis.
The purpose of this work was to finalize the biological diagnosis of
patients with FVIII activity deficiency in Abidjan in order to guide
the best type of management.
Patients and Methods
|Table 1. Classification of patients by age group.|
|Table 2. Circumstances of discovery of the disease.|
|Table 3. Factor VIII level by age|
|Table 4. vWF Quantitative (vWF: Ag) and Functional (vWF: Ac) Assays.|
|Table 5. Results of the FVIII, vWF: Ag and vWF: Ac assays for each patient.|